Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.01
64.79
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Guangzhou Kingmed Diagnostics Group Co Ltd
Guangzhou Kingmed Diagnostics Group Co Ltd
Free Cash Flow
Guangzhou Kingmed Diagnostics Group Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
|
Free Cash Flow
¥532.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Jinxin Fertility Group Ltd
HKEX:1951
|
Free Cash Flow
¥510.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Topchoice Medical Co Inc
SSE:600763
|
Free Cash Flow
¥349.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
18%
|
|
|
Nanjing Xinjiekou Department Store Co Ltd
SSE:600682
|
Free Cash Flow
¥511.7m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dian Diagnostics Group Co Ltd
SZSE:300244
|
Free Cash Flow
¥1.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
46%
|
CAGR 10-Years
55%
|
|
|
Meinian Onehealth Healthcare Holdings Co Ltd
SZSE:002044
|
Free Cash Flow
¥1.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
Glance View
Guangzhou Kingmed Diagnostics Group Co Ltd has crafted its journey in the healthcare industry with precision and analytical prowess. Emerging in the early 2000s, Kingmed Diagnostics tapped into a burgeoning market niche—offering diagnostic testing services to hospitals, clinics, and other medical institutions. With a blend of advanced technology and extensive scientific expertise, the company provides a range of services, from routine clinical testing to esoteric evaluations that require more sophisticated techniques. Kingmed’s laboratories, strategically established across China, facilitate a seamless operation that processes millions of tests annually, ensuring timely and accurate results. This operational efficiency not only supports healthcare providers in delivering informed patient care but also positions Kingmed at the forefront of diagnostic innovation. Revenue streams flow through service contracts with healthcare facilities and direct partnerships where they provide specialized testing offerings that institutions may not have the infrastructure to perform in-house. By leveraging economies of scale, Kingmed achieves cost efficiencies, which in turn afford competitive pricing structures, further securing its market position. Complementing its robust diagnostic services, the company also invests in research and development initiatives, continuously enhancing its test portfolio. This commitment to innovation ensures that they stay relevant in the ever-evolving healthcare landscape, capturing new opportunities and expanding their market reach. Through this strategic framework, Guangzhou Kingmed Diagnostics not only sustains its financial growth but also fortifies its leadership in the diagnostic services sector.
See Also
What is Guangzhou Kingmed Diagnostics Group Co Ltd's Free Cash Flow?
Free Cash Flow
532.5m
CNY
Based on the financial report for Sep 30, 2024, Guangzhou Kingmed Diagnostics Group Co Ltd's Free Cash Flow amounts to 532.5m CNY.
What is Guangzhou Kingmed Diagnostics Group Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
11%
Over the last year, the Free Cash Flow growth was 56%. The average annual Free Cash Flow growth rates for Guangzhou Kingmed Diagnostics Group Co Ltd have been -12% over the past three years , 11% over the past five years .
You don't have any saved screeners yet